PA
TGNA

PharVision Advisers’s TEGNA Inc TGNA Stock Holding History

PharVision Advisers’s Portfolio TGNA Stock Details TGNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,160
Closed -$332K – 505
2024
Q4 		$332K Buy
+18,160
New +$318K 0.28% 123

Other funds holding TGNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PharVision Advisers's TGNA Position: Q1 2025 in Review

PharVision Advisers sold out of TEGNA Inc (TGNA) in Q1 2025, closing a stake of 18,160 shares — an estimated $332K sold.

PharVision Advisers first reported a position in TGNA in Q4 2024 and held it in 1 quarter. The position peaked at $332K in Q4 2024. 366 funds tracked by Wall St. Rank hold TGNA as of Q1 2025.

  • PharVision Advisers reported no remaining TEGNA Inc position as of Q1 2025 after selling out during the quarter.
  • PharVision Advisers sold 18,160 TEGNA Inc shares in Q1 2025, an estimated $332K.
  • PharVision Advisers first reported a position in TEGNA Inc in Q4 2024 and held it in 1 quarter.
  • PharVision Advisers's TEGNA Inc position peaked at $332K in Q4 2024.
  • 366 funds tracked by Wall St. Rank held TEGNA Inc as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.